JP2022507506A5 - - Google Patents
Info
- Publication number
- JP2022507506A5 JP2022507506A5 JP2021526492A JP2021526492A JP2022507506A5 JP 2022507506 A5 JP2022507506 A5 JP 2022507506A5 JP 2021526492 A JP2021526492 A JP 2021526492A JP 2021526492 A JP2021526492 A JP 2021526492A JP 2022507506 A5 JP2022507506 A5 JP 2022507506A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862768804P | 2018-11-16 | 2018-11-16 | |
| US62/768,804 | 2018-11-16 | ||
| US201862769165P | 2018-11-19 | 2018-11-19 | |
| US201862769151P | 2018-11-19 | 2018-11-19 | |
| US62/769,165 | 2018-11-19 | ||
| US62/769,151 | 2018-11-19 | ||
| US201962795913P | 2019-01-23 | 2019-01-23 | |
| US62/795,913 | 2019-01-23 | ||
| US201962796356P | 2019-01-24 | 2019-01-24 | |
| US201962796361P | 2019-01-24 | 2019-01-24 | |
| US62/796,361 | 2019-01-24 | ||
| US62/796,356 | 2019-01-24 | ||
| US201962802621P | 2019-02-07 | 2019-02-07 | |
| US62/802,621 | 2019-02-07 | ||
| US201962895954P | 2019-09-04 | 2019-09-04 | |
| US62/895,954 | 2019-09-04 | ||
| PCT/US2019/061533 WO2020102576A1 (en) | 2018-11-16 | 2019-11-14 | Compounds and compositions for treating conditions associated with nlrp activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507506A JP2022507506A (ja) | 2022-01-18 |
| JP2022507506A5 true JP2022507506A5 (https=) | 2022-11-21 |
| JPWO2020102576A5 JPWO2020102576A5 (https=) | 2022-11-21 |
Family
ID=68808610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526492A Pending JP2022507506A (ja) | 2018-11-16 | 2019-11-14 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230051589A1 (https=) |
| EP (1) | EP3880659B1 (https=) |
| JP (1) | JP2022507506A (https=) |
| CN (1) | CN113286784A (https=) |
| TW (1) | TW202033504A (https=) |
| WO (1) | WO2020102576A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| PH12022551767A1 (en) * | 2020-01-22 | 2023-11-29 | Hoffmann La Roche | Sulfonimidamide compounds as nlrp3 modulators |
| EP3984535A1 (en) * | 2020-10-16 | 2022-04-20 | Albert-Ludwigs-Universität Freiburg | Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome |
| CN114539256B (zh) * | 2020-11-20 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 三环化合物及其医药用途 |
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CN118302415A (zh) * | 2021-12-03 | 2024-07-05 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物的制备方法 |
| CN116804018A (zh) * | 2022-03-25 | 2023-09-26 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| CN114989058B (zh) * | 2022-06-02 | 2024-04-16 | 中国科学院成都生物研究所 | 一种手性氯代砜亚胺类化合物及其衍生物的制备方法 |
| EP4561574A1 (en) * | 2022-07-27 | 2025-06-04 | Novartis AG | Dosing regimen for a nlrp3 inhibitor |
| CN115961298B (zh) * | 2022-12-31 | 2024-10-01 | 广西师范大学 | 一种电化学介导乙烯基苯胺与醇合成2，3-二烷氧基取代吲哚啉化合物、合成方法及应用 |
| TW202502747A (zh) * | 2023-03-17 | 2025-01-16 | 美商凡特斯治療美國公司 | 用於抑制ｎｌｒｐ３之醯胺衍生物及其用途 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3259253T1 (sl) * | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| WO2018225018A1 (en) * | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| ES2988798T3 (es) * | 2017-07-24 | 2024-11-21 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| EP3692020A1 (en) * | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| CA3105521A1 (en) * | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
-
2019
- 2019-11-14 WO PCT/US2019/061533 patent/WO2020102576A1/en not_active Ceased
- 2019-11-14 EP EP19817076.3A patent/EP3880659B1/en active Active
- 2019-11-14 CN CN201980085505.3A patent/CN113286784A/zh active Pending
- 2019-11-14 JP JP2021526492A patent/JP2022507506A/ja active Pending
- 2019-11-14 US US17/293,781 patent/US20230051589A1/en not_active Abandoned
- 2019-11-15 TW TW108141694A patent/TW202033504A/zh unknown